Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

Concentration of beta2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-alpha therapy

Tadeusz Wojciech Łapiński, Aldona Kot, Danuta Prokopowicz

Med Sci Monit 2002; 8(7): CR538-542 :: ID: 510717

Abstract

Background: We evaluated the serum β2,-MG concentration and CD4 lymphocytes in the blood of HCV infected patients during IFN-α therapy, searching for a correlation between β2,-MG concentration, CD4 lymphocytes, and therapy effectiveness, as well as morphological changes in the liver.
Material/Methods: patients with chronic HCV infection were treated with IFN-α2a. The serum β2,-MG concentration was measured with the use of a method based on the fluorescent modification of the immunoenzymatic technique. The percentage of T CD4 lymphocytes in the blood was measured by direct immunofluorescence using monoclonal antibodies.
Results: The number of CD4 lymphocytes in the blood was lower in the HCV infected patients (864/ml; preferred values from 1,300 to 2,100/ml), the β2,-MG concentration was elevated (2.37 mg/dl) in comparison to the preferred values (1.52 mg/dl; p<0.05). IFN-α therapy caused an increase in the β2,-MG. The highest increase was observed among patients who did not eliminate the virus (from 2.39 to 4.10 mg/dl). In the initial period of interferon therapy an increase was observed (from 729 to 1082/ml) in the number of CD4 lymphocytes among those patients who eliminated the virus and a decrease (from 947 to 853/ml) in the patients who were not treated successfully.
Conclusions: A significant increase in β2,-MG during interferon therapy in patients with chronic HCV infection is a predictor of poor outcome. An increase in the number of CD4 lymphocytes in the initial phase of treatment suggests a positive outcome.

Keywords: IFN-α therapy, HCV infection, β2-MG

Add Comment 0 Comments

Editorial

01 April 2024 : Editorial  

Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance

Dinah V. Parums

DOI: 10.12659/MSM.944600

Med Sci Monit 2024; 30:e944600

0:00

In Press

10 Apr 2024 : Clinical Research  

Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...

Med Sci Monit In Press; DOI: 10.12659/MSM.942612  

06 Mar 2024 : Clinical Research  

Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...

Med Sci Monit In Press; DOI: 10.12659/MSM.941102  

06 Mar 2024 : Clinical Research  

Prevalence and Variation of Medical Comorbidities in Oral Surgery Patients: A Retrospective Study at Jazan ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943884  

08 Mar 2024 : Clinical Research  

Evaluation of Foot Structure in Preschool Children Based on Body Mass

Med Sci Monit In Press; DOI: 10.12659/MSM.943765  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750